Merck Acquisition of Terns Pharmaceuticals Advances with HSR Waiting Period Expiration
Summary
Merck's tender offer for Terns Pharmaceuticals progresses as the HSR waiting period expires, despite a new stockholder lawsuit challenging the transaction.
Key Events
-
HSR Waiting Period Expires
The waiting period under the Hart-Scott-Rodino Act expired on April 23, 2026, satisfying a key condition for Merck's tender offer to acquire Terns Pharmaceuticals. This follows the initial tender offer statement filed on April 7, 2026.
-
Stockholder Lawsuit Filed
A purported stockholder filed a complaint on April 10, 2026, alleging misleading disclosures related to the tender offer. Terns and Merck believe the claims are without merit, and Terns has also received additional demand letters from other stockholders.
-
Tender Offer Price Confirmed
Merck's subsidiary, Thailand Merger Sub, Inc., continues its offer to acquire all outstanding shares of Terns for $53.00 per share in cash, without interest and subject to withholding taxes.
Analysis
This amendment to the Schedule TO provides key updates on Merck's tender offer to acquire Terns Pharmaceuticals for $53.00 per share. The expiration of the Hart-Scott-Rodino Act waiting period removes a significant regulatory hurdle, indicating progress towards the deal's completion. However, the disclosure of a new stockholder lawsuit and demand letters introduces a potential, though common, challenge to the transaction. The market is currently pricing Terns' stock very close to the offer price, reflecting high confidence in the acquisition closing.
At the time of this filing, TERN was trading at $52.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $2.66 to $53.19. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.